We investigated the effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on peripheral blood progenitor cell (PBPC) mobilization and the combined effect of PEGrHuMGDF plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) in C57BL/6 mice. 
Bone marrow transplantation (BMT) and peripheral blood progenitor cell (PBPC) transplantation are widely used for hematopoietic reconstitution after myeloablative therapy in various diseases. Recently, there has been an increased use of PBPC transplantation because rapid hematopoietic engraftment can be expected after transplantation and discomforts and risks associated with multiple bone marrow punctures under general anesthesia can be avoided.
To mobilize and collect a sufficient number of PBPCs for autologous and allogeneic transplantation, granulocyte colony-stimulating factor (G-CSF) has been preferentially used. G-CSF-mobilized PBPCs retain long-term reconstituting ability. 1, 2 However, the use of G-CSF at higher doses frequently causes adverse effects such as bone pain, headache, and general fatigue. 3 Furthermore, some patients or donors will show 'poor mobilization' in which a sufficient number of PBPCs for sustained engraftment cannot be collected following G-CSF administration.
Other cytokines such as stem cell factor (SCF), macrophage inflammatory protein-1␣, interleukin-6 (IL-6), IL-7, IL-8, IL-11 and flt-3 ligand have been reported to mobilize PBPCs, and some of them can enhance PBPC mobilization in synergy with G-CSF. [4] [5] [6] [7] [8] [9] [10] [11] [12] Thrombopoietin (TPO), a ligand for cytokine receptor, c-Mpl acts not only as a primary regulator of megakaryocytopoiesis and thrombopoiesis but also as an enhancer of proliferation of committed erythroid and primitive hematopoietic progenitors. [13] [14] [15] [16] [17] [18] [19] [20] [21] Several investigators described accelerated multilineage hematopoietic recovery with TPO treatment in myelosuppressed animals and patients after chemotherapy. [22] [23] [24] [25] [26] [27] It has been also reported that TPO is effective to mobilize PBPC in mice and humans. [28] [29] [30] Treatment of BDF1 mice with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), a pegylated, truncated molecule related to TPO, strongly stimulates expansion of a circulating pool of committed and multipotent progenitors, including colony-forming units (CFU) megakaryocyte (CFU-MK), burst-forming units erythroid (BFU-E), CFU granulocyte-macrophage (CFU-GM) and multipotent CFU containing the erythroid lineage (CFUMix). Combined administration of PEG-rHuMGDF and recombinant human (rh)G-CSF induces a synergistic effect Bone Marrow Transplantation on the increase in these progenitors in PB. 30 Day 12 spleen colony-forming units (CFU-S), more primitive progenitors, are also mobilized into PB by PEG-rHuMGDF injection. 30 In the clinical setting, it has been reported that administration of TPO or PEG-rHuMGDF to humans results in mobilization of CFU-GM, BFU-E, CFU-MK, and CD34 + cells into PB, and adverse effects associated with PEGrHuMGDF administration have been reported to be negligible. 26, 27, [31] [32] [33] We have investigated whether PEG-rHuMGDF is different from rhG-CSF in the pattern or potential for PBPC mobilization in mice and whether their combination will induce a synergistic effect on PBPC mobilization. We assayed day 8 and day 12 CFU-S, and pre-CFU-S, which are more primitive progenitors with marrow repopulating ability (MRA), in PB from mice treated with rhG-CSF and/or PEG-rHuMGDF, and found that PBPC mobilization pattern and potential were different between PEGrHuMGDF and rhG-CSF and that synergistic effects on PBPC mobilization could be induced by them in combination.
Materials and methods

Animals
Male and female C57BL/6 mice were bred and kept in the mouse colony of our institution. All animals were housed in conventional cages with four to five animals in each cage, and received nonsterilized food and water ad libitum. These mice were used between 6 and 8 weeks of age.
Cytokines
Both rhG-CSF and PEG-rHuMGDF were supplied by Kirin Brewery Co. Ltd (Tokyo, Japan).
Mobilization of PBPCs
Some groups of four male mice were injected intravenously with PEG-rHuMGDF daily at doses of 37.5-300 g/kg for 5-10 days or subcutaneously with rhG-CSF daily at doses of 125-500 g/kg for 5 days, and the others were injected with a combination of both cytokines. Twenty-four hours after the last injection, PB was harvested from the orbital plexus using heparinized syringes.
CFU-S assay
Day 8 and day 12 CFU-S were assayed according to the method of Till and McCulloch. 34 Briefly, recipient mice were irradiated with a lethal dose of 8.0 Gy with X-rays (MBR-1520R; Hitachi, Tokyo, Japan; dose rate: 0.8 Gy/min at 125 kV and 15 mA with 1.0 mm Al + 0.5 mm Cu filters, focus and sample distance: 40 cm), and 10-50 l of PB from donor mice treated with rhG-CSF and/or PEGrHuMGDF or untreated mice was injected intravenously through a tail vein into 10 to 16 recipients in each treatment regimen. Eight or 12 days later, the recipient mice were killed by cervical dislocation and their spleens were removed and fixed with Bouin's solution. 35 Visible surface colonies were counted and scored as CFU-S. Control mice, which had only been irradiated, showed no macroscopic spleen nodules on days 8 or 12.
Pre-CFU-S (MRA) assay
PB in a volume of 200 l from donor mice or untreated mice was injected intravenously into four to five recipient mice that had been lethally irradiated. Thirteen days after the injection, the recipient mice were killed and their BM cell suspensions were obtained by flushing the femurs with 1 ml of Iscove's modified Dulbecco's medium (IMDM; GIBCO BRL, Grand Island, NY, USA). Two hundred microliters of suspension containing 2 × 10 5 BM cells was then injected into the secondary irradiated recipient mice (n = 5-8) for CFU-S assays. The number of pre-CFU-S was expressed as the number of day 12 CFU-S per femur in the primary recipient per milliliter of PB initially injected. 36 
PBPC transplantation and Y-chromosome polymerase chain reaction (PCR) analysis
PB (300 l) from male donor mice treated with rhG-CSF and/or PEG-rHuMGDF was injected intravenously into female recipient mice that had been lethally irradiated.
Approximately 4 months later, PB from the recipients was collected and donor-derived hematopoiesis in the female recipients was determined by analyzing DNA in PB samples. PCR analysis of the DNA sequence specific for murine Y chromosome and murine platelet-derived growth factor (PDGF) B receptor was performed according to the method of Yan et al 5 with some modifications. Briefly, 10 l of heparinized PB was added to 90 l of H 2 O. The samples were boiled for 15 min, incubated on ice for 5 min, and centrifuged at 14 000 r.p.m. for 10 min. Twenty-five microliters of the supernatant was used for PCR amplification. The samples were heated to 94°C for 4 minutes and then amplified for 35 cycles at 94°C for 1 min, 52°C for 1 min, and 72°C for 2 min in 50 l of PCR reaction solution containing 50 pmol of mouse Y chromosomespecific primers or mouse PDGF B receptor-specific primers and 1.25 units Takara Taq (Takara, Tokyo, Japan). Amplification with Y chromosome-specific primers resulted in a 722 bp fragment corresponding to mouse Sry locus sequence 256-978, while amplification with PDGF B receptor-specific primers, as a control for the PCR amplification, generated an approximately 750 bp fragment corresponding to mouse PDGF B receptor cDNA sequence 948-1166. Amplified materials were electrophoresed in 1% agarose gel and detected by staining with ethidium bromide.
Statistical analysis
Data are expressed as mean ± s.e.m and Student's t-test was employed for statistical evaluation. A P value of Ͻ0.05 was considered statistically significant. 
Results
CFU-S assay
Groups of mice received different doses of cytokines for 5 or 10 days, and PB was collected for measuring day 8 and day 12 CFU-S. At a dose of 75 g/kg/day, PB collected after 10 days' administration of PEG-rHuMGDF contained more CFU-S (day 8, 480 ± 23/ml PB; day 12, 467 ± 35/ml PB) than that collected after 5 days of administration (day 8, 120 ± 23/ml; day 12, 130 ± 25/ml) (P Ͻ 0.001 on days 8 and 12; Figure 1 ). At doses ranging from 0 to 150 g/kg/day for 10 days, the number of CFU-S in PB was increased in a dose-dependent fashion (Figure 2 ). However, at a higher dose of 300 g/kg/day, no further increase in the number of CFU-S was observed. Thus, we considered that the optimal dose and duration of PEGrHuMGDF administration for PBPC mobilization in male C57BL/6 mice were 150 g/kg/day and 10 days, respectively.
Similarly, we examined the dose-response relationship between rhG-CSF and PBPC mobilization in C57BL/6 mice. It has been reported that PBPC mobilization potential Bone Marrow Transplantation is similar with daily divided doses and a daily single dose of G-CSF, 37 so we administered various doses of rhG-CSF to donor mice subcutaneously once a day and found that the optimal dose of rhG-CSF was 250 g/kg/day for 5 days (day 8 CFU-S, 337 ± 42/ml; day 12 CFU-S, 600 ± 34/ml; Figure 3) .
We examined whether a combination of rhG-CSF and PEG-rHuMGDF could induce synergistic effects on PBPC mobilization. The concurrent administration of optimal doses of the two cytokines significantly increased the numbers of day 8 and day 12 CFU-S in PB (day 8, 1875 ± 149/ml; day 12, 3075 ± 138/ml) compared to either factor alone (P Ͻ 0.001 on days 8 and 12; Figure 4 ). Furthermore, suboptimal doses of the two cytokines, 125 g/kg/day of rhG-CSF plus 75 g/kg/day of PEGrHuMGDF, mobilized significantly higher number of day 8 and day 12 CFU-S into PB (day 8, 1267 ± 88/ml; day 12, 1733 ± 88/ml) than their optimal doses (P Ͻ 0.005 on days 8 and 12).
Pre-CFU-S (MRA) assay
Next we performed a pre-CFU-S assay to evaluate mobilization of more primitive progenitors by these two cytokines in PB. Both rhG-CSF and PEG-rHuMGDF mobilized pre-CFU-S into PB ( Figure 5 ). However, the number of pre-CFU-S mobilized by PEG-rHuMGDF was significantly lower than that by rhG-CSF (PEG-rHuMGDF, 170 ± 25/ml; rhG-CSF, 360 ± 29/ml; P Ͻ 0.005). When a combination of optimal doses of these two cytokines was administered, the number of pre-CFU-S mobilized was significantly increased (1334 ± 849/ml; P Ͻ 0.001).
PBPC transplantation and Y chromosome polymerase chain reaction (PCR) analysis
To further assess long-term marrow repopulating activity of the mobilized PBPCs, PB samples collected from female recipients that survived at approximately 4 months after PBPC transplantation were tested for the presence of Y chromosome-specific sequences by PCR. All of three longterm surviving female mice transplanted with PBPCs mobi- Treatment pre-CFU-S (/ml blood) Figure 5 Effects of the administration of PEG-rHuMGDF and/or rhG-CSF on mobilization of pre-CFU-S into PB. Mice were treated with an optimal dose of PEG-rHuMGDF for 10 days or rhG-CSF for 5 days, or the combination of the two factors (PEG-rHuMGDF on days 1-10 and rhG-CSF on days 6-10), and PB was collected on day 11 for measuring pre-CFU-S. Values represent the mean ± s.e.m. of two experiments each from four to six mice. G125+T75, rhG-CSF at 125 g/kg/day for 5 days plus PEG-rHuMGDF at 75 g/kg/day for 10 days.
lized by an optimal dose of rhG-CSF showed positivity for the Y chromosome. Similarly, all of 14 long-term surviving recipients transplanted with PBPCs mobilized by an optimal dose of PEG-rHuMGDF alone or the combination of suboptimal or optimal doses of rhG-CSF plus PEGrHuMGDF showed donor type hematopoietic reconstitution ( Figure 6 ).
Discussion
Previous studies have shown that G-CSF mobilizes CFU-S and long-term repopulating stem cells into PB in mice and that TPO or PEG-rHuMGDF can mobilize various types of hematopoietic progenitor cells such as colony-forming units in culture (CFU-C), day 12 CFU-S in mice, and CD34
+ cells in human. 1, [28] [29] [30] [31] [32] In this study, we investigated
Sry (Y chromosome)
PDGF
Figure 6
Long-term MRA of PBPCs mobilized by PEG-rHuMGDF and/or rhG-CSF. Male donor mice were treated with rhG-CSF at 250 g/kg/day for 5 days, PEG-rHuMGDF at 150 g/kg/day for 10 days, or the combination of the two factors (PEG-rHuMGDF on days 1-10 and rhG-CSF on days 6-10), and PB was collected on day 11 and transplanted into lethally irradiated female recipients. Four months after transplantation, PB from the recipients was collected and analyzed for sequences specific for murine Y chromosome and murine platelet-derived growth factor (PDGF) B receptor, as a control, by PCR. Controls were male and female DNA samples. G125+T75, rhG-CSF at 125 g/kg/day for 5 days plus PEG-rHuMGDF at 75 g/kg/day for 10 days.
PBPC mobilization potentials of PEG-rHuMGDF and a combined effect of PEG-rHuMGDF plus rhG-CSF. Our data of CFU-S assays showed that appropriate doses of PEG-rHuMGDF could mobilize both day 8 and day 12 CFU-S into PB of normal C57BL/6 mice. Ten days' administration of PEG-rHuMGDF mobilized significantly more day 8 CFU-S into PB than 5 days' administration of rhG-CSF (P Ͻ 0.005), and there were no significant differences in the number of day 12 CFU-S mobilized between PEGrHuMGDF and rhG-CSF.
We also studied mobilization of pre-CFU-S into PB. Although both rhG-CSF and PEG-rHuMGDF mobilized pre-CFU-S, the number of pre-CFU-S mobilized by PEGrHuMGDF alone was significantly lower than that mobilized by rhG-CSF alone (P Ͻ 0.005). This difference was not observed in CFU-S mobilization.
It has been reported that day 8 CFU-S are neither multipotential nor self-renewing but committed to lineage differentiation while day 12 CFU-S contain relatively primitive progenitor cells. 35 Furthermore, pre-CFU-S have been reported to be more primitive progenitor cells with MRA. 36 Our data showed that PEG-rHuMGDF alone could mobilize not only relatively committed progenitor cells but also immature progenitor cells with long-term MRA into PB, and suggest that PEG-rHuMGDF alone has a sufficient potential for PBPC mobilization. However, mainly relatively committed progenitor cells were mobilized by PEGrHuMGDF whereas rhG-CSF mobilized mainly immature progenitor cells. Also, a longer duration of PEG-rHuMGDF administration was needed for mobilizing progenitor cells as efficiently as rhG-CSF. These data imply that the pathways of PBPC mobilization may be different for these two cytokines. A variety of cytokine combinations for PBPC mobilization has been tested in animal models. [4] [5] [6] [7] [8] [9] [10] 12, 30 Combined administration of appropriate doses of PEG-rHuMGDF and rhG-CSF induces a synergistic effect on CFU-C mobilization potential compared to either factor alone. 30 This observation is consistent with our data showing that the concurrent administration of optimal or sub-optimal doses of PEG-rHuMGDF and rhG-CSF could induce a synergistic effect on mobilization of day 8, day 12, and pre-CFU-S in PB compared to PEG-rHuMGDF or rhG-CSF alone. Moreover, PCR analysis showed that PBPCs mobilized by PEGrHuMGDF plus rhG-CSF retained the long-term MRA, like G-CSF-mobilized PBPCs. It has been reported that administration of rhG-CSF to mice induces hematopoietic progenitor cells in BM to first move into PB and then proliferate, and therefore the number of progenitor cells in BM is significantly reduced after administration of rhG-CSF. 10, 38 On the other hand, after 5 days of treatment with PEGrHuMGDF, a significant expansion of progenitor cells in BM precedes the maximal increase in circulating PBPCs. 30, 39 In our experiments, we administered PEGrHuMGDF on days 1-10 and rhG-CSF on days 6-10 to mice, and collected their PB on day 11 for measuring CFU-S. It is possible that previous administration of PEGrHuMGDF on days 1-5 caused expansion of hematopoietic progenitor cells in BM and enhanced the PBPC mobilization potential of rhG-CSF.
Administration of high-dose G-CSF for PBPC mobilization frequently causes adverse effects in a dose-dependent fashion. 3 On the other hand, adverse effects associated with PEG-rHuMGDF or TPO administration have been reported to be negligible. 26, 27, 31, 33 Our data suggest that the additive and precedent administration of PEG-rHuMGDF may provide a sparing effect of G-CSF dose to reduce its adverse effects, and can mobilize a sufficient number of PBPCs with long-term MRA for transplantation. Furthermore, our data indicate that PEG-rHuMGDF alone or the combination with rhG-CSF may be useful for mobilization of PBPCs in donors of 'poor mobilization', in which a sufficient number of PBPCs for sustained engraftment are not mobilized and harvested after administration of rhG-CSF alone.
Further studies are needed to explore the mechanism of PBPC mobilization and to find the optimal condition for the combination effects of PEG-rHuMGDF and rhG-CSF on PBPC mobilization in mice and in humans.
